Crizotinib CAS 877399-52-5 Assay ≥99.0% API Factory High Quality
Shanghai Ruifu Chemical Co., Ltd. minangka produsen utama Crizotinib (CAS: 877399-52-5) kanthi kualitas dhuwur.Ruifu Chemical bisa nyedhiyakake pangiriman ing saindenging jagad, rega sing kompetitif, layanan sing apik, jumlah cilik lan akeh sing kasedhiya.Tuku Crizotinib,Please contact: alvin@ruifuchem.com
| Jeneng Kimia | Crizotinib |
| sinonim | Xalkori;PF-02341066;Crozotinib;Crizotinib Xalkori;3-[1-(2,6-Dichloro-3-Fluoro-fenil)-ethoxy]-5-(1-Piperidin-4-yl-1H-pirazol-4-yl)-piridin-2-ylamine;(R)-3-[1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-yl-1H- pyrazol-4-yl)piridin-2-ylamine |
| Nomer CAS | 877399-52-5 |
| Status Simpenan | Ing Stok, Skala Produksi Nganti Atusan Kilogram |
| Formula Molekul | C21H22Cl2FN5O |
| Bobot Molekul | 450.34 |
| Titik Lebur | 192 ℃ |
| Kapadhetan | 1,47±0,10 g/cm3 |
| Suhu panyimpenan | Suhu Kamar |
| asale | Shanghai, China |
| Merk | Kimia Ruifu |
| Item | Spesifikasi |
| Penampilan | Bubuk Putih nganti Putih |
| Identifikasi | Miturut IR, HPLC |
| Kejelasan Solusi | Selaras karo Standar |
| Mundhut ing Pangatusan | ≤1,00% |
| Sisa ing Ignition | ≤0,50% |
| Related Impurities | (dening HPLC) |
| Impurity Tunggal | ≤0,50% |
| Total Impurities | ≤1,00% |
| Logam abot | ≤20ppm |
| Assay | ≥99,0% |
| Sisa Solvents | Ketemu Spesifikasi |
| Urip beting | 24 wulan |
| Test Standar | Standar Perusahaan |
Paket:Botol, tas Aluminium foil, 25kg / Drum Karton, utawa miturut kabutuhan pelanggan.
Kondisi panyimpenan:Tansah wadhah ditutup kanthi rapet lan simpen ing gudang sing adhem, garing (2 ~ 8 ℃) lan kanthi ventilasi sing adoh saka bahan sing ora cocog.Nglindhungi saka cahya lan Kelembapan.
Pengiriman:Ngirim menyang donya liwat udhara, dening FedEx / DHL Express.Nyedhiyakake pangiriman sing cepet lan dipercaya.
Katrangan Keamanan 24/25 - Aja kena kulit lan mripat.
UN ID UN 3077 9 / PGIII
WGK Jerman 3
Kode HS 2933990099
Kelas Bahaya IRRITANT
Crizotinib (CAS 877399-52-5), (Crizotinib, Xalkori R), minangka inhibitor molekul cilik kompetitif ATP sing kuat lan selektif saka ALK lan c-Met.Ing Agustus 2011, FDA Amerika Serikat nyetujoni Crizotinib kanggo perawatan kanker paru-paru non-sel cilik (NSCLC) anaplastic lymphoma kinase (ALK).Crizotinib minangka inhibitor kompetitif ATP ganda saka tyrosine kinase c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50 = 8 nM) lan ALK (cellular IC50 = 20 nM), loro-lorone minangka target penting kanggo kemoterapi kanker.Nalika crizotinib dites kanggo selektivitas lawan kinase liyane, ditemokake duwe enzim IC50 ing kelipatan 100 kali c-MET kanggo 13 saka 120 kinase sing diuji.Ing tes seluler, crizotinib ditemokake kanggo nyandhet RON (recepteur d'origine nantais) kinase kanthi jendela selektivitas kaping 10 liwat c-MET.
Crizotinib (PF-02341066) Crizotinib minangka inhibitor c-Met lan ALK sing kuat, nilai IC50 ing uji sel yaiku 11 nM lan 24 nM, masing-masing.Iki uga minangka inhibitor kuat ROS1 kanthi nilai Ki kurang saka 0,025 nM.Crizotinib bisa nyebabake autophagy ing macem-macem garis sel kanker paru-paru kanthi nyandhet jalur STAT3.
Crizotinib minangka inhibitor ganda sing kuat lan selektif saka mesenchymal-epithelial transition factor (c-MET) kinase lan limfoma kinase anaplastik (ALK).Crizotinib minangka agen antitumor potensial.Ing wulan Agustus 2011, FDA Amerika Serikat nyetujoni crizotinib kanggo perawatan kanker paru-paru non-sel cilik (NSCLC) anaplastic lymphoma kinase (ALK).
Crizotinib (Xalkori(R), Pfizer), disetujoni ing 2011, minangka inhibitor sing disetujoni pisanan sing nargetake anaplastic lymphoma kinase (ALK).ROS protooncogene 1-encoded kinase (ROS1) saka kelas reseptor insulin kinase tirosin lan kinase sing dienkode proto-onkogen MET saka kelas reseptor faktor pertumbuhan hepatosit (HGFR) minangka kinase liyane sing ditargetake dening crizotinib. Nalika disetujoni ing 2011, crizotinib minangka sing pisanan. obat khusus nargetake pasien NSCLC.Nanging, resistensi kanggo crizotinib biasane diamati ing kira-kira 8 sasi sawise aplikasi awal lan luwih saka setengah pasien sing diobati karo crizotinib ngalami efek samping gastrointestinal.Ing 2016, crizotinib uga disetujoni kanggo NSCLC positif ROS1 dening FDA.
Crizotinib (Xalkori) minangka inhibitor tirosin kinase reseptor lisan sing dituduhake kanggo perawatan pasien kanker paru-paru non-sel cilik (NSCLC) lanjut utawa metastatik.Efek samping sing umum nalika nggunakake Xalkori kalebu infeksi saluran napas ndhuwur, mual, mutahke, nyeri weteng, nyuda napsu, insomnia, pusing, rasa kesel, diare, konstipasi, ruam utawa gatel, gejala kadhemen (irung sesak, wahing, tenggorokan), mati rasa utawa tingling, utawa dadi gedhe ing tangan utawa sikil.
